LeMaitre goes it alone in Italy:
This article was originally published in Clinica
Executive Summary
Vascular device manufacturer LeMaitre Vascular will sell its products in Italy through its own Rome-based sales force from January 2008 as part of its strategy to establish a worldwide direct sales operation. The Burlington, Massachusetts-based company will terminate its partnership with Serom Medical Technologies, which currently has exclusive Italian distribution rights to the products, on January 25. Serom will provide a range of consulting services to facilitate the transition. The move will incur a charge of $1.1m, which LeMaitre will record in Q3 2007. The firm has direct sales operations in the UK, Japan, the Benelex region, Austria, Sweden and France.
You may also be interested in...
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.